Skip to main content
logo
Thermo Fisher Scientific Inc. (VIE:TMOF)
Austria flag Austria · Delayed Price · Currency is EUR
398.35
+4.55 (1.16%)
At close: Sep 30, 2025

Revenue by Product

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202012 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2012 - 2019
Other
1.00M
Log In
Log In
Log In
Log In
Upgrade
Life Sciences Solutions
9.63B
Log In
Log In
Log In
Log In
Upgrade
Life Sciences Solutions Growth
3.03%
Log In
Log In
Log In
Log In
Upgrade
Analytical Instruments
7.46B
Log In
Log In
Log In
Log In
Upgrade
Analytical Instruments Growth
2.48%
Log In
Log In
Log In
Log In
Upgrade
Specialty Diagnostics
4.51B
Log In
Log In
Log In
Log In
Upgrade
Specialty Diagnostics Growth
3.49%
Log In
Log In
Log In
Log In
Upgrade
Laboratory Products and Biopharma Services
23.16B
Log In
Log In
Log In
Log In
Upgrade
Laboratory Products and Biopharma Services Growth
1.67%
Log In
Log In
Log In
Log In
Upgrade
Consumables
17.59B
Log In
Log In
Log In
Log In
Upgrade
Consumables Growth
2.92%
Log In
Log In
Log In
Log In
Upgrade
Instruments
7.45B
Log In
Log In
Log In
Log In
Upgrade
Instruments Growth
-0.65%
Log In
Log In
Log In
Log In
Upgrade
Services
17.85B
Log In
Log In
Log In
Log In
Upgrade
Services Growth
2.30%
Log In
Log In
Log In
Log In
Upgrade
Other
1.00M
Log In
Log In
Log In
Log In
Upgrade

EBIT by Product

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202012 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2012 - 2019
Other
-1.97B
Log In
Log In
Log In
Log In
Upgrade
Other Growth
-19.86%
Log In
Log In
Log In
Log In
Upgrade
Life Sciences Solutions Operating Income
3.50B
Log In
Log In
Log In
Log In
Upgrade
Life Sciences Solutions Operating Income Growth
2.25%
Log In
Log In
Log In
Log In
Upgrade
Analytical Instruments Operating Income
1.96B
Log In
Log In
Log In
Log In
Upgrade
Analytical Instruments Operating Income Growth
-2.80%
Log In
Log In
Log In
Log In
Upgrade
Specialty Diagnostics Operating Income
1.16B
Log In
Log In
Log In
Log In
Upgrade
Specialty Diagnostics Operating Income Growth
3.16%
Log In
Log In
Log In
Log In
Upgrade
Laboratory Products and Biopharma Services Operating Income
3.09B
Log In
Log In
Log In
Log In
Upgrade
Laboratory Products and Biopharma Services Operating Income Growth
-2.26%
Log In
Log In
Log In
Log In
Upgrade
Other
-1.97B
Log In
Log In
Log In
Log In
Upgrade
Other Growth
-19.86%
Log In
Log In
Log In
Log In
Upgrade

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202012 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2012 - 2019
North America
22.50B
Log In
Log In
Log In
Log In
Upgrade
North America Growth
1.66%
Log In
Log In
Log In
Log In
Upgrade
Europe
10.86B
Log In
Log In
Log In
Log In
Upgrade
Europe Growth
2.42%
Log In
Log In
Log In
Log In
Upgrade
Asia-Pacific
7.96B
Log In
Log In
Log In
Log In
Upgrade
Asia-Pacific Growth
1.51%
Log In
Log In
Log In
Log In
Upgrade
Other Regions
1.56B
Log In
Log In
Log In
Log In
Upgrade
Other Regions Growth
7.91%
Log In
Log In
Log In
Log In
Upgrade

Other

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202012 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2012 - 2019
Total Organic Revenue Growth
-
Log In
Log In
Log In
Log In
Upgrade
Core Organic Revenue Growth
-
Log In
Log In
Log In
Log In
Upgrade